GAD2 and type 1 diabetes mellitus: This strategy has yielded promising results through suppression of Th1-mediated responses across multiple animal models of autoimmunity, including murine EAE using intranasal delivery of full MBP antigen (232), EAMG using nicotinic acetylcholine receptor (AChR) antigen (248), CIA using collagen II antigen, and the type 1 diabetes mouse model of non-obese diabetes (NOD) using GAD65 antigen (15).